Formulary
Lumasiran: Indications, Dosing, Side Effects and Interactions
Lumasiran is a double-stranded small interfering RNA, which reduces production of the enzyme glycolate oxidase involved in the synthesis of glyoxylate and...
MedNext Academy | 3 min read
Lumasiran: Indications, Dosing, Side Effects and Interactions
Lumasiran is a double-stranded small interfering RNA, which reduces production of the enzyme glycolate oxidase involved in the synthesis of glyoxylate and...
Drug action
Lumasiran is a double-stranded small interfering RNA, which reduces production of the enzyme glycolate oxidase involved in the synthesis of glyoxylate and oxalate, thereby reducing urinary and plasma oxalate levels.
Indications and dose
**Primary hyperoxaluria type 1 (under expert supervision)**
- **Adult** (By Subcutaneous Injection): Loading dose 3 mg/kg once a month for 3 doses, then maintenance 3 mg/kg every 3 months, to be started 1 month after the last loading dose.
**Primary hyperoxaluria type 1 (under expert supervision) for lumasiran**
- **Neonate (body-weight up to 10 kg)** (By subcutaneous injection): Loading dose 6 mg/kg once a month for 3 doses, then maintenance 3 mg/kg once a month, to be started 1 month after the last loading dose.
- **Child (body-weight up to 10 kg)** (By subcutaneous injection): Loading dose 6 mg/kg once a month for 3 doses, then maintenance 3 mg/kg once a month, to be started 1 month after the last loading dose.
- **Child (body-weight 10-19 kg)** (By subcutaneous injection): Loading dose 6 mg/kg once a month for 3 doses, then maintenance 6 mg/kg every 3 months, to be started 1 month after the last loading dose.
- **Child (body-weight 20 kg and above)** (By subcutaneous injection): Loading dose 3 mg/kg once a month for 3 doses, then maintenance 3 mg/kg every 3 months, to be started 1 month after the last loading dose.
Side effects
Common or very common Gastrointestinal discomfort
Pregnancy
Use only if potential benefit outweighs risk (limited information available). M
Breast feeding
Avoid (no information available). M
Hepatic impairment
Caution in moderate or severe impairment (potential for decreased efficacy). M
Renal impairment
Monitor for signs and symptoms of metabolic acidosis in severe impairment (increased plasma-glycolate levels caused by lumasiran therapy may increase the risk of, or worsen pre-existing, metabolic acidosis).
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Lumasiran in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

